Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v22-EN | Version v20-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2024-04-05 | 2024-01-17 |
| Drug Identification Number | 02471469 | 02471469 |
| Brand name | OZEMPIC | OZEMPIC |
| Common or Proper name | Ozempic | Ozempic |
| Company Name | NOVO NORDISK CANADA INC | NOVO NORDISK CANADA INC |
| Ingredients | SEMAGLUTIDE | SEMAGLUTIDE |
| Strength(s) | 1MG | 1MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 1 | 1 |
| ATC code | A10BJ | A10BJ |
| ATC description | ||
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2023-08-21 | 2023-08-21 |
| Actual start date | ||
| Estimated end date | 2024-03-31 | 2024-03-31 |
| Actual end date | 2024-01-17 | 2024-01-17 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | Yes |
| Company comments | Due to the combination of overall global supply constraints coupled with increased demand, Novo Nordisk Canada Inc. is experiencing continued temporary delays on the shipments and delivery of Ozempic®. While we continue to manufacture and ship Ozempic®, patients may experience delays. We are working hard to address this issue and taking all relevant actions to ensure a continuous supply of medicine to Canadian patients. We will continue to monitor wholesale orders for extreme exceptions above normal demand, ensuring equal access for our patients | Due to the combination of overall global supply constraints coupled with increased demand, Novo Nordisk Canada Inc. is experiencing continued temporary delays on the shipments and delivery of Ozempic®. While we continue to manufacture and ship Ozempic®, patients may experience delays. We are working hard to address this issue and taking all relevant actions to ensure a continuous supply of medicine to Canadian patients. We will continue to monitor wholesale orders for extreme exceptions above normal demand, ensuring equal access for our patients |
| Health Canada comments |